Eight cadaver donor r enal allograft recipients, who had received azathioprine and prednisone from the day of transplantation, were treated with OKT3 monoclonal antibody (reactive with all m ature peripheral blood T cells ) at the time of diagnosis of acute rejection. In all cases, loss of essentially all detectable peripheral blood OKT3-reactive cells was n oted within minutes after the initial 1-to 5-mg i.v. in.fusion. Chills and fever invariably occurred following the first or second in.fusion of monoclonal antibody, but were not noted during the subsequent 10-to 20-day course of therapy, suggesting rapid cell lysis as the etiology of this toxicity.
Eight cadaver donor r enal allograft recipients, who had received azathioprine and prednisone from the day of transplantation, were treated with OKT3 monoclonal antibody (reactive with all m ature peripheral blood T cells ) at the time of diagnosis of acute rejection. In all cases, loss of essentially all detectable peripheral blood OKT3-reactive cells was n oted within minutes after the initial 1-to 5-mg i.v. in.fusion. Chills and fever invariably occurred following the first or second in.fusion of monoclonal antibody, but were not noted during the subsequent 10-to 20-day course of therapy, suggesting rapid cell lysis as the etiology of this toxicity.
The established rejection episode was reversed in all cases within 2 to 7 days without addition of any therapy other than OKT3 antibody and despite continued lowering of the steroid dosages. During the subsequent 3-to 12-month follow-up period, further rejection episodes occurred in five of these patients, two of these were irreversible with conventional therapy so that six of the e ight allografts continue with excellent renal function.
These preliminary observations suggest that homogeneity, limited dosage requirements, and ease of in vitro monitoring of dosage effects should markedly simplify the u se of monoclonal antibody to T cell populations in human allograft recipients. This second generation of antilymphocyte preparations offers the potential for not only increased effectiveness but also the possibility of manipulating specific T cell s ubsets.
Although some heterologous antisera to human lymphocytes have proved to be effective in delaying or reversing allograft rejection (1, 2), the preparation of these agents has been difficult using conventional immunization techniques. Even the purified IgG fraction from animals immunized with lymphocytes contains not only a heterogeneous group of antibodies to T lymphocytes, but also antibodies reactive with other normal cells as well as extraneous antibodies reflecting the animal's previous . ~unological activity (3) . T herefore, techniques of developing .,. · 'more'specific reagents· have been sought.
Based upon the recent demonstration by Kohler and Milstein (4) that monoclonal antibody to a specific membrane determinant can be reliably produced using cell hybridization techniques, Kung et al (5) have produced a panel of monoclonal antibodies specifically. reactive with human lymphocyte subpopulations. A phylogenetic screen of these reagents in our laboratory revealed significant cross-reactivity of some of them with lymphocytes of subhuman primates. In order to evaluate the possible clinical role of monoclonal antibody as an immunosuppressive agent, we previously investigated in cynomolgus renal allograft recipients the effects ofOKT4 antibody (6) . This antibody is reactive with human T cells having major helper/ inducer and T-T collaborative functions (7, 8) . By using flow cytometry for monitoring of peripheral blood lymphocytes, we defined the dosage and timing ofOKT4 antibody administration required to provide in vivo coating of this specific T cell population now in 10 cynomolgus recipients. With a dosage range of 0.5 to 1.0 mg/kg/day, coating of all reactive cells was observed and residual circulating Ab was usually detectable 24 hr after administration. When OKT4 therapy was started before transplantation, allograft survival was extended to as long as 7 weeks after a 1-to 2-week course ofthe. rapy (control survival 8 to 11 days).
Encouraged by the effectiveness, ease of administration, and lack o( toxicity in this in vivo model, we have begun a trial of monoclonal antibody therapy in human renal allograft recipients. Although the ultimate goal is to evaluate only selected T cell subset suppression, in order to expose the patients in this initial study to the least risk of ineffective immunosuppression, we have tested 0 KT3 antibody which is reactive with all mature human T cells (9, 10) .
MATERIALS AND METHODS
Eight cadaver donor renal recipients, who had received azathioprine and prednisone from the time of transplantation, were treated with OKT3 monoclonal antibody at the time of diagnosis of acute rejection. Allograft rejection was suggested in these patients by deterioration in renal function and was confirmed in all patients by histopathological evaluation of tissue obtained by percutaneous needle biopsy.
In the attempt to identify the most effective and least toxic combination of conventional and OKT3 therapy, se:v.eral dosage schedules were pursued. In the first two patients, azathioprine was administered in a dosage of 10 mg/kg on the day of transplantation and then maintained at 1 to 2 mg/kg/ day unless the white blood count fell below 3000/mm 3 . Prednisone was begun at a daily dosage of 2 mg/ kg. Beginning on the 5th postoperative day, the dosage was decreased by 10 mg/ day to 0.8 mg/ kg/ day, after which the dosage was more slowly tapered to the maintenance dosage of 0.25 mg/kg/ day. Following confirmation of the diagnosis of rejection, OKT3 antibody was administered by bolus i.v. injection in a total daily dosage of 1 to 2 mg for 10 days. In the next two patients, the azathioprine was reduced to 0.75 mg/kg/day and prednisone dosage to 0.6 535 mg/kg/day during OKT3 therapy which was ad.ministered i.v. in a total daily dosage of 1 to 3 mg for 14 days. In the last four patients, the azathioprine and prednisone dosages were further reduced to 0.4 mg/ kg/ day during OKT3 therapy. In these patients OKT3 was administered daily for 14 to 20 days at a dosage of 4 to 5 mg/day (Fig. 1) . After discontinuing OKT3 therapy, the azathioprine dosage was again increased to 1 to 2 mg/kg/day in the last six patients.
Prior to transplantation, during azathioprine and prednisone therapy, and at frequent intervals after institution of OKT3 antibody therapy, peripheral blood lymphocytes from buffy coat preparations were analyzed for OKT3-reactive cells using flow cytometry (JJ). Recipient serum was monitored by incubating sequentially diluted sera with normal human peripheral blood lymphocytes, followed by staining with fluoresceinated goat anti-mouse antibody, in order to detect and maintain a circulating level of OKT3 antibody. Effectiveness of therapy was judged by reversal of rejection defined as the day after which consistent improvement in renal function occurred. Percutaneous renal biopsies were performed on all patients after OKT3 therapy.
Toxicity was studied by daily monitoring of recipient complete blood count, blood urea nitrogen, and creatinine, weekly assays of hepatic function and urine protein excretion, and careful observation for any clinical evidence of serum sickness. Serial urine, salivary, and buffy coat specimens were cultured for viral activity as previously described (12) .
RESULTS
The clinical course of a representative patient treated with OKT3 antibody is depicted in Figure 1 . Following cadaver donor renal transplantation in this 41-year-old male, the serum creatinine level fell to normal levels by the 4th post-transplant day. Subsequently, the onset of rejection was suggested by the rising serum creatinine level which occurred in conjunction with decreased urinary output, weight gain, hypertension, and low-grade fever. Allograft biopsy confirmed the diagnosis on the 7th post-transplant day and the initial 5-rng dose of OKT3 antibody was infused i.v. after an i.d. skin challenge was observed to produce no reaction. Approximately 45 min later, an episode of shaking chills with fever to 101 C occurred. In addition, the patient complained of shortness of breath and diffuse wheezes were noted over the lung fields. These symptoms rapidly responded to acetaminophen and antihistamine therapy. The patient had no further chills, fever, or other adverse reactions with subsequent OKT3 infusions.
Sequential monitoring of peripheral blood lymphocytes was begun 15 min after the initial injection. As noted in Figure 1 , there was essentially complete loss of OKT3-reactive cells from the peripheral circulation, a condition which persisted throughout the 14-day course of therapy. That this was not attributable to masking or modulation of OKT3 antigen was indicated by the failure of fluorescein conjugates of OKT4 and OKT8 monoclonal antibodies, which bind to other T cell antigens (11) , to react with the residual cells. In addition, detectable antibody excess was present throughout the course of therapy during which a total dosage of 70 mg of OKT3 antibody was administered.
The serum creatinine level continued to rise for several days after institution of therapy but the patient's clinical condition rapidly improved with diuresis, weight loss, and improved control of blood pressure being noted within 36 hr of initiation of treatment. Continuous improvement in renal function began 72 hr after OKT3 treatment was initiated with the serum creatinine eventually stabilizing at 1.3 mg/100 ml As depicted in Figure 1 , the azathioprine and steroid dosages were rapidly tapered during this period. A second allograft biopsy performed on the last day of therapy showed essentially complete resolution of the histopathological findings of rejection (Fig. 2) .
The initial results of treatment of the eight patients studied arc summarized in Tables 1 and 2 . In every instance, the rejection episode for which OKT3 the. rapy was instituted was reversed with steady improvement in allograft function beginning after 2 to 7 days of therapy. In the first three patients and the last patient treated, a subsequent rejection episode occurred beginning 2 to 6 weeks after cessation of OKT3 therapy while the patients were being maintained on azathioprine and prednisone. These episodes were easily reversed in three of these patients with increased steroids. The second rejection episode in patient 3, however, could not be reversed despite increased steroids, local irradiation, and actinomycin D therapy. She returned to dialysis 2 months after transplantation. She subsequently developed severe cytomegalovirus infection and expired 3 months after transplantation.
1''1GURE 2. Histopathological picture of renal allograft biopsies before (left) and after (right) OKT3 monoclonal antibody therapy. Almost complete disappearance of the interstitial mononuclear infiltrate and reversal of endothelial damage is noted after treatment.
Patient 4 is of particular interest because of the development during therapy of an antibody response to the OKT3 reagent. During the initial 10 days of therapy, peripheral blood T cell monitoring of this patient revealed essentially complete loss of cells reactive with OKT3 antibody, and allograft function steadily improved from a peak serum creatinine of 8.1to2.9 mg/100 ml. During the final 4 days of OKT3 therapy, however, large numbers of OKT3-reactive cells were repeatedly demonstrable in the patient's peripheral blood and no serum excess of OKT3 could be achieved even after the dosage of monoclonal antibody had been increased from 2 to 5 mg/day. At the time, the steadily falling serum creatinine again began to rise and allograft biopsy revealed extensive evidence of acute rejection. The immunosuppressive protocol was immediately changed to conventional therapy with high-dose steroids, local irradiation, and actinomycin D; but the rejection process continued, necessitating allograft nephrectomy 31 days after transplantation. Evaluation of serial serum samples from this patient by flow cytometry documented the appearance of anti-OKT 3 antibody initially on day 10 of therapy with the titer peaking 5 days after therapy was discontinued. Characterization of these antibodies will be reported in detail elsewhere. No evidence of serum sickness or anaphylaxis was noted at any time in this patient.
Therefore, six of the eight allografts continue with excellent renal function 3 to 12 months after OKT3 treatment. All of the patients treated with OKT3 antibody developed chills and fever •Reversed with conventional immunosuppression. 6 Irreversible using conventional immunosuppression.
< On hemodialysis.
to as high as 102 C within 1 hr of the first injection, and several were noted to have diffuse wheezing during this period. No reactions to subsequent injections were noted and no other evidence of toxicity could be identified. The effective removal of OKT3-reactive cells (mature T lymphocytes) from the circulation within minutes after infusion of OKT3 antibody was clearly documented by flow cytometry analysis in each case. This dramatic lysis of cells occurred only with the first injection, the OKT3-reactive population then remaining depressed (except in patient 4) throughout the course of therapy.
DISCUSSION
Whether improved long-term allograft survival can be achieved with such therapy remains to be established; however, some observations regarding the addition of monoclonal antibody to conventional therapy can be made. In the first four patients, the attempt was made to use the minimum total irnmunosuppression which would produce reversal of the rejection episode. Thus, the dosage of OKT3 antibody administered was limited to that (1 to 2 mg/day) which maintained a barely detectable serum antibody level. In each case, except patient 4 who developed anti-OKT3 antibodies, all clinical manifestations of rejection were abolished. However, post-therapy allograft biopsies showed persistent cellular infiltration and recurrent rejection requiring conventional high-dose steroid therapy appeared within 2 to 6 weeks. All of these patients subsequently A central problem in transplantation remains that of incom-suffered significant oral infection secondary to herpes simplex pletely controlled rejection. Intense, nonspecific suppression of virus and cytomegalovirus pnewnonitis was documented after the recipient's immune system is produced with currently used the second rejection episode in two of the patients, one of whom ·agents but the level of clinical success and toxicity has changed subsequently died. These observations appear to emphasize the little over the past decade. The only significant addition to this previously proposed concept that a modestly high-dose "net regimen has been the gradual acceptance of heterologous anti-state of immunosuppression" over a prolonged period of time is lymphocyte preparations such as antilymphocyte globulin, an-probably of greater risk to patients than a limited, more intentithymocyte globulin (ATG), etc. (13) , with which a more sive course of therapy (12) . In the next four patients, therefore, selective suppression of the recipient's cellular immune re-the dosage of OKT3 antibody was sharply increased in an sponses is anticipated. However, with currently available attempt to reverse more definitively the rejection activ.ity duragents, prepared by routine immunization techniques, only 5 to ing a limited period of therapy. In addition, as in our studies 10% of the total dose administered represents the actual ther-with ATG (14) , we have continued to try to limit the dosages of apeutic product. As hybridoma technology bas developed, the azathioprine and prednisone administered during the period in possibility of producing anti-T cell monoclonal antibodies with which the patients received OKT3 antibody. To date, the effecti~ness similar to currently used ATG preparations but clinical course in these patients has been much more satisfacwhich are active in much smaller quantities has been realized. tory. Furthermore, the feasibility of using antibodies to suppress Unacceptable in vivo toxicity of monoclonal antibody adminselected T cell subsets rather than the entire population can istration has not been observed. The chills, febrile response, now be tested.
and occasional wheezing noted on the first day of treatment The results of our studies have begun to delineate the in vivo have been found to be readily controlled with antihistamine effects of such reagents. We have observed significant immu-and acetaminophen therapy. These symptoms have been noted nosuppression in subhuman primate renal allograft recipients with ATG treatment as well (15) and have been thought to be receiving relatively minute quantities of monoclonal antibody secondary to release of endogenous pyrogens following exten-(total recipient dosage: 17 to 56 mg compared with 50 to 100 sive lysis of peripheral blood lymphocytes. The observations in mg/kg/ day (14) when using heterologous ATG preparations)· the patients treated with OKT3 antibody would tend to support Moreover, the OKT4 antibody administered to these recipients such an explanation, for the chills and fever were noted only has been shown to be directed only to the helper/inducer T cell after the first infusion concomitant with the dramatic drop in subset, reacting with approximately 50 to 60% of human pe-the number of circulating T lymphocytes. Subsequent infusions ripheral blood T cells and 45 ± 9% of cynomolgus T cells. These were tolerated without similar incidents. It is hoped that later observations demonstrate not only the immunosuppressive po-morbidity, primarily infection, can be minimized if an approtency of monoclonal antibody..but also that effective prQtoc~~ .,,priate dosage of monoclonal antibody can be defined which will may be developed in which the requirement for agents, which . maximize control of rejection without the addition of other produce indiscriminate T cell depression, might be markedly agents. It might then be anticipated that long-term morbidity reduced.
would be less than with conventional therapy, since it is genIn our previous clinical evaluation of equine ATG, we have erally accepted that serious complications are most likely to found the most definitive means of demonstrating effectiveness occur when large doses of steroids are required to reverse was in studies in which ATG alone was added to the immuno. ··rejection activity.
· ·: . , , , . . ,. · .. suppressive protocol at the time of diagnosis of acute rejection
In conclusion, these observations suggest that the homoge-(2). Since only a single agent is being used to reverse a readily neity, limited dosage requirements, and ease of in vitro monidefined event, it is possible to elucidate immediately the effect toring of the effects of monoclonal antibody upon T cell popuof the added therapy without the need for long-term random-lations in the peripheral blood will simplify their application to ized trials. Thus, we have pursued a similar model for the patient management. Although, to date, only a reagent reactive evaluation of monoclonal antibody. We have selected OKT3 with all peripheral blood T cells has been evaluated in patients, antibody rather than antibody to a T cell subpopulation in the possibility of manipulating selected T cell subsets is now at order to reduce the likelihood of inadequate suppression in this hand. initial trial. Our most important clinical observation in the patients treated to date has been the initial reversal in all cases of the established rejection episode without addition of any therapy other than OKT3 antibody and despite continued lowering of the steroid dosage. 
